Jesper van Eck van der Sluijs

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 4

Top Topics

Stem Cell Transplantation

Randomized Controlled Trial

Top Venues

Clinical & translational immunology

Cancer immunology, immunotherapy : CII

Cellular and molecular life sciences : CMLS

Journal for immunotherapy of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Eline J H van Houtum, Anne Hc Valk, Daniel Granado, Jasper Lok, Lune van den Bogaard, Naomi Remkes, Jesper van Eck van der Sluijs, Paul N Span, Lenneke A M Cornelissen, Gosse J Adema
Siglec-7 and Siglec-9 expression in primary triple negative and oestrogen receptor positive breast cancer and in vitro signalling. Clinical & translational immunology 13 (9) (2024)
Nataschja I Ho, Lisa G M Huis In 't Veld, Jesper van Eck van der Sluijs, Branco M H Heuts, Maaike W G Looman, Esther D Kers-Rebel, Koen van den Dries, Harry Dolstra, Joost H A Martens, Willemijn Hobo, Gosse J Adema
Saponin-based adjuvants enhance antigen cross-presentation in human CD11c + CD1c + CD5 - CD163 + conventional type 2 dendritic cells. Journal for immunotherapy of cancer 11 (8) (2023)
Jesper van Eck van der Sluijs, Diede van Ens, Jolanda Brummelman, Daan Heister, Aastha Sareen, Lisa Truijen, Dorette S van Ingen Schenau, Mirjam H M Heemskerk, Marieke Griffioen, Michel G D Kester, Nicolaas P M Schaap, Joop H Jansen, Anniek B van der Waart, Harry Dolstra, Willemijn Hobo
Human CD34 + -derived complete plasmacytoid and conventional dendritic cell vaccine effectively induces antigen-specific CD8 + T cell and NK cell responses in vitro and in vivo. Cellular and molecular life sciences : CMLS 80 (10) (2023)
Jesper van Eck van der Sluijs, Diede van Ens, Soley Thordardottir, Denise Vodegel, Inge A T Hermens, Anniek B van der Waart, J H Frederik Falkenburg, Michel G D Kester, Iris de Rink, Mirjam H M Heemskerk, Jannie Borst, Nicolaas P M Schaap, Joop H Jansen, Yanling Xiao, Harry Dolstra, Willemijn Hobo
Clinically applicable CD34+-derived blood dendritic cell subsets exhibit key subset-specific features and potently boost anti-tumor T and NK cell responses. Cancer immunology, immunotherapy : CII 70 (11) (2021)